Enforcement

ICH Q9 Quality Risk Management in Pharma

Conference Spotlight

Drug GMP Warning Letter Issued Without Facility Inspection

Conference Spotlight

FDA Post-Warning Letter Meetings are Not Agency Consultations

Audience Q&A: From Legal Considerations when Interacting with the FDA Webinar

Enforcement

Internal Audit Reports: Can the FDA Take a Peek? Part 2: Other Agencies

Enforcement

Expert Commentary | Updates to FDA’s Manual of Policies and Procedures (MAPP)

Peter Baker’s Roadmap to Quality Intelligence

Conference Spotlight

A Deep Dive into Cell and Gene Therapy Regulatory Considerations: Part Two

Enforcement

Internal Audit Reports: Can the FDA Take a Peek?

Conference Spotlight

Is Raw FDA Data Skewing Your Analyses?

Conference Spotlight

Should ICH Tackle Standard Development for CGT Products?

Conference Spotlight

Post-Approval Change Management Protocol Pilot Aims to Reduce Approval Time

Conference Spotlight

Navigating Drug Approvals and Post-Approval Changes in the Asia-Pacific Region

Why am I Being Inspected Again So Soon After a Pre-Approval Inspection?

Conference Spotlight

How To Get Drug Products Approved In Asia-Pacific Markets

Conference Spotlight

Getting Drugs Approved in Mexico, Argentina, Colombia, And Peru

Good Quality, Poor Quality in the Pharmaceutical Industry

Conference Spotlight

How to Get New Drugs Approved in Brazil

Redica Responds: How Many GMP Inspections Have Resulted in a 483?

Conference Spotlight

CMC Challenges and Opportunities in Latin America

Regulatory Expectations for Cleaning Validation

Redica Responds: Insights on Media Fill Enforcement Trends

GMP Audits: What Are They and Why Are They Important?

A Short Guide to GMP Process Validation

What Can Trigger a CAPA?